These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36949118)

  • 41. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19 Delta variation; more contagious or more pernicious?
    Yazdanpanah F; Yazdanpanah S; Rezaei N
    Acta Biomed; 2022 Jan; 92(6):e2021454. PubMed ID: 35075065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses.
    Kannan SR; Spratt AN; Cohen AR; Naqvi SH; Chand HS; Quinn TP; Lorson CL; Byrareddy SN; Singh K
    J Autoimmun; 2021 Nov; 124():102715. PubMed ID: 34399188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 lineage B.6 was the major contributor to early pandemic transmission in Malaysia.
    Chong YM; Sam IC; Chong J; Kahar Bador M; Ponnampalavanar S; Syed Omar SF; Kamarulzaman A; Munusamy V; Wong CK; Jamaluddin FH; Chan YF
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008744. PubMed ID: 33253226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada.
    Fibke CD; Joffres Y; Tyson JR; Colijn C; Janjua NZ; Fjell C; Prystajecky N; Jassem A; Sbihi H
    Front Public Health; 2022; 10():915363. PubMed ID: 35859775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contrasting Epidemiology and Population Genetics of COVID-19 Infections Defined by Multilocus Genotypes in SARS-CoV-2 Genomes Sampled Globally.
    Chan FHM; Ataide R; Richards JS; Narh CA
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural Profiles of SARS-CoV-2 Variants in India.
    Chakraborti S; Gill J; Goswami R; Kumar S; Chandele A; Sharma A
    Curr Microbiol; 2022 Nov; 80(1):1. PubMed ID: 36414797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4405-4412. PubMed ID: 34227076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dynamic change of SARS-CoV-2 variants in Sierra Leone.
    Lin L; Zhang J; Rogers J; Campbell A; Zhao J; Harding D; Sahr F; Liu Y; Wurie I
    Infect Genet Evol; 2022 Mar; 98():105208. PubMed ID: 34999288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Description of a One-Year Succession of Variants of Interest and Concern of SARS-CoV-2 in Venezuela.
    Jaspe RC; Loureiro CL; Sulbaran Y; Moros ZC; D'Angelo P; Hidalgo M; Rodríguez L; Alarcón V; Aguilar M; Sánchez D; Ramírez J; Garzaro DJ; Zambrano JL; Liprandi F; Rangel HR; Pujol FH
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An entropy-based study on mutational trajectory of SARS-CoV-2 in India.
    Santoni D; Ghosh N; Saha I
    Infect Genet Evol; 2022 Jan; 97():105154. PubMed ID: 34808395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using high-resolution melting analysis.
    Aoki A; Adachi H; Mori Y; Ito M; Sato K; Okuda K; Sakakibara T; Okamoto Y; Jinno H
    J Toxicol Sci; 2021; 46(10):471-476. PubMed ID: 34602531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spatiotemporal characteristics of the SARS-CoV-2 Delta wave in North Carolina.
    Pang CJ; Delamater PL
    Spat Spatiotemporal Epidemiol; 2023 Jun; 45():100566. PubMed ID: 37301588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Bioinformatics Tool for Predicting Future COVID-19 Waves Based on a Retrospective Analysis of the Second Wave in India: Model Development Study.
    Kumar A; Asghar A; Dwivedi P; Kumar G; Narayan RK; Jha RK; Parashar R; Sahni C; Pandey SN
    JMIR Bioinform Biotechnol; 2022; 3(1):e36860. PubMed ID: 36193192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Second wave of COVID-19 in India: Dissection of the causes and lessons learnt.
    Choudhary OP; Priyanka ; Singh I; Rodriguez-Morales AJ
    Travel Med Infect Dis; 2021; 43():102126. PubMed ID: 34144178
    [No Abstract]   [Full Text] [Related]  

  • 59. Corrigendum: SARS-CoV-2 evolution among patients with immunosuppression in a nosocomial cluster of a Japanese medical center during the Delta (AY.29 sublineage) surge.
    Hosaka Y; Yan Y; Naito T; Oyama R; Tsuchiya K; Yamamoto N; Nojiri S; Hori S; Takahashi K; Tabe Y
    Front Microbiol; 2024; 15():1478638. PubMed ID: 39247696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India.
    Tripathy AS; Singh D; Trimbake D; Salwe S; Tripathy S; Kakrani A; Jali P; Chavan H; Yadav P; Sahay R; Sarje P; Babar P; Shete A; Nandapurkar A; Kulkarni M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2410579. PubMed ID: 39434214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.